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1. Introduction  
Platelets play a central role in hemostasis and thrombosis, initiating clot formation in 
response to vessel wall damage. Platelet aggregates are formed at sites of injury by the 
binding and crosslinking of the integrin IIb3 to fibrinogen, von Willebrand factor and 
other soluble ligands. Platelets also form pathological thrombi, and the resulting arterial 
occlusion can lead to myocardial infarction or stroke. Inhibition of IIb3 binding can 
decrease the formation of pathologic thrombi, and IIb3 has become an important 
pharmacological target. Anti-IIb3 therapies have been highly successful in preventing 
death following myocardial infarction and percutaneous arterial stent placement.(Topol, 
Lincoff et al. 2002; De Luca, Ucci et al. 2009) However, attempts to design novel, orally 
available anti-IIb3 agents have been hampered by what appears to be paradoxical 
activation of IIb3 by the drug, in some cases leading to an increased risk of mortality in 
patients who received the drug.(Quinn, Plow et al. 2002)  
A novel approach to manipulatingIIb3 would be to perturb its post-translational 
processing and trafficking within the megakaryocyte, prior to platelet formation. Like most 
membrane proteins, IIb3 is formed by concerted processes of protein sorting and 
trafficking. Some of the mechanisms underlying IIb3 biogenesis and expression in 
megakaryocytes have been described, such as the calnexin cycle of protein quality 
control.(King and Reed 2002; Tiwari, Italiano et al. 2003; El.Golli, Issertial et al. 2005; Lo, Li 
et al. 2005) Clues to the stringent protein quality control of IIb3 biogenesis come from the 
study of patients with defective or absent IIb3, who manifest the mucocutaneous bleeding 
disorder Glanzmann thrombasthenia. A subset of patients with mutations in the IIb gene 
produce full-length IIb that retains the ability to form a complex with 3 but is retained 
within the cell and degraded, resulting in disease. These patients demonstrate the existence 
of stringent quality control mechanisms acting post-translationally to control IIb3 
biogenesis and expression. A clearer understanding of these mechanisms may lead to new 
possibilities of anti-integrin therapy. 
Toward the goal of identifying proteins involved in IIb3 biogenesis we performed a 
proteomic analysis of proteins interacting with IIb in megakaryocytes cultured from 
human umbilical cord blood (UCB) and in HEK293 cells expressing IIb and 3. 
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Megakaryocyte proteins were captured by poly-histidine tagged IIb, or by photoreactive 
crosslinking followed by immunoprecipitation with anti-IIb mAbs, and analyzed by mass 
spectrometry.  
The IIb and b3 subunits are synthesized as a single-chain precursors in the chaperone-rich 
folding environment of the endoplasmic reticulum (ER) (Fig 1). The precursor IIb, pro-
IIb, is glycosylated under control of the calnexin cycle of protein folding. The 3 precursor 
is also glycosylated but does not appear to interact with the calnexin cycle. The two 
precursors heterodimerize to briefly form pro-IIb3, and then pro-IIb is cleaved by one or 
more members of the furin family of proteases in the Golgi. Cleavage of pro-IIb to mature 
IIb marks the exit of IIb from the ER, and this cleavage occurs only when pro-IIb is in 
complex with 3.(Bray, Rosa et al. 1986; Rosa and McEver 1989) Both IIb and 3 are 
synthesized in excess of what will finally be processed to mature IIb3. The calnexin cycle 
exerts stringent quality control over IIb production and up to one half of all pro-IIb is 
targeted to the proteasome for degradation in megakaryocytes. Excess 3 is degraded by a 
non-proteasomal mechanism. Inhibition of the proteasome in megakaryocytes resulted in a 
build-up of pro-IIb that was not being degraded, but had no apparent effect on the level of 
mature IIb in the IIb3 complex. Thus, the expression level of mature IIb3 is not simply 
a result of the stoichiometry of production vs. degradation. Rather there appears to be a 
concerted mechanism that controls how much pro-IIb3 will be converted into mature 
IIb3, and this mechanism is not grossly responsive to excessive levels of pro-IIb or 3.  
 
Fig. 1. Biogenesis of IIb3 
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We hypothesized that whatever proteins underlie this mechanism must be interacting with 
pro-IIb and/or pro-IIb3 complex, but not with the mature IIb3 complex. We chose a 
proteomics approach to identify these interacting proteins. In order to enrich our assay for 
proteins that preferentially bound pro-IIb or pro-IIb3, we used an IIb subunit 
harboring R858G and R859G mutations that eliminates furin cleavage and traps IIb in its 
pro-IIb form.(Kolodziej, Vilaire et al. 1991) This IIbR858G/R859G construct can form a 
complex with 3, but only in small amounts compared to normal IIb3. In addition, while 
some of the mutant IIb3 complexes reach the cell surface and can mediate adherence to 
immobilized fibrinogen, the proportion of IIbR858G/R859G reaching the surface is very 
small compared to normal IIb.(Kolodziej, Vilaire et al. 1991)  Thus, IIbR858G/R859G is a 
“nearly normal” mutant IIb subunit that is primarily retained within the cell, making it a 
useful bait to capture the proteins involved in that process.  
The hsp40 type chaperone protein, DNAJC10, was captured by both the normal IIb and 
IIbR858G/R859G subunits, and was evaluated as a putative IIb interacting protein.. We 
report that DNAJC10 interacted with pro-IIb and 3 in megakaryocytes, and appears to 
promote the degradation of pro-IIb. Notably, while IIb3-DNAJC10 interaction was 
evident in megakaryocytes, specific interaction was not detectable in HEK293 cells 
transfected with IIb cDNA, suggesting megakaryocyte specificity. Knockdown of 
DNAJC10 by siRNA increased IIb3 surface expression in UCB derived megakaryocytes, 
indicating that DNAJC10 negatively regulates IIb3 surface expression. Thus, DNAJC10-
IIb interaction represents a novel post-translational mechanism regulating IIb3 surface 
expression.  
2. Materials and methods 
2.1 Antibodies 
The antibodies used in this study were: 10E5 (anti-IIb3 complex); B1B5 (anti-IIb);7H2 
and B36 (anti-3) (all 4 generous gifts from Dr Barry Coller); CA3 (anti-IIb), anti-V5 
epitope, and anti-Myc epitope (all three Millipore, Temecula,CA); anti-DNAJC10 (Genetex, 
Irvine, CA); M148 (anti-IIb) (Santa Cruz Biotechnology, Santa Cruz, CA); mouse IgG, and 
rabbit IgG (both Jackson ImmunoResearch Inc, West Grove, PA). 
2.2 Human Umbilical Cord Blood culture 
This study used human UCB from the US National Cord Blood Bank that was deemed not 
suitable for clinical use due to low white blood cell number. Mothers who donate their UCB 
to the National Cord Blood Bank sign a consent giving permission to donate the UCB to 
research if it is inadequate for clinical use and will be discarded. Because the donated units 
are completely de-identified and are not collected prospectively specifically for research, the 
New York Blood Center Institutional Review Board (IRB), which oversees research ethics at 
the National Cord Blood Bank, considers their use exempt from IRB review. Human UCB 
was prepared as previously described.(Mitchell, Li et al. 2006) Briefly, leukocytes were 
separated from 1-3 units of human UCB judged to be inadequate for clinical purposes 
(generously provided by the New York Blood Center) by Dextran 70 sedimentation 
(Amersham Biosciences, Piscataway, NJ) for 1h, and then enriched for CD34+ progenitor 
www.intechopen.com
 Hematology – Science and Practice 
 
174 
cells by negative selection using a combination of antibodies against maturation/lineage-
specific markers (RosetteSep, StemCell Technologies, Vancouver, BC) concomitant with 
density sedimentation using Ficoll-Paque Plus (Amersham Biosciences, Piscataway, NJ). 
These cells were cultured in serum-free medium (StemCell Technologies, Vancouver, BC) 
with 50 ng/ml thrombopoietin (TPO) plus 1 ng/ml SCF (both Millipore, Temecula,CA) for 3 
days in 10 cm dishes in a 37°C incubator. At this point a portion of the cells will have died. 
The remaining living population of larger cells was gently washed and replated in fresh 
media with the same cytokines in 10 cm dishes and left until use (Day 8 or 9). Fresh media 
was added on day 6. We have previously reported that under these conditions the UCB 
differentiate into a population of large cells with > 90% expressing IIb3, > 80% expressing 
GPIb, about 50% expressing 21.(Mitchell, Li et al. 2007) For experimental use the cells 
were gently harvested, pelleted at 300 rpm for 5 min, or let settle by gravity, and gently 
resuspended in the appropriate buffer. 
2.3 HEK293 cell culture 
HEK293  cell lines (American Type Culture Collection (ATCC), Manassas, VA) that stably 
expressed human IIb3 receptors were established as previously described.(Mitchell, Li et 
al. 2006) Transfections were performed using Lipofectamine 2000 (Gibco-BRL, Carlsbad, 
CA) according to the manufacturer’s instructions, followed by selection in media containing 
500 g/ml G418 for 2-4 weeks. To obtain a population of cells uniformly expressing high 
levels of IIb3, cells were labeled with the mAb 10E5 (anti-IIb3) and sorted using a 
MoFlo cell sorter (Beckman Coulter, Fullerton, CA).  
2.4 Immunoprecipitation and biosynthetic labeling 
Samples were prepared as previously described and all steps were performed on ice unless 
otherwise stated.(Mitchell, Li et al. 2006) Briefly, cells (either day 8 megakaryocytes derived 
from UCB cells or HEK293 cells) were lysed in 1% Brij 98 lysis buffer containing protease 
inhibitors and 20uM N-methylmaleimide (NEM). Lysates were precleared with protein-G 
Sepharose beads (Amersham Biosciences, Piscataway, NJ), and then equivalent amounts of 
protein, usually 400 g, were incubated one h at 4C with one or more of the antibodies 
listed above (4 g/reaction). Samples were incubated with protein-G Sepharose beads for 
one h at 4C, washed twice, and incubated with SDS sample buffer for 10 min at 100°C. 
Reduced samples contained 10% beta mercaptoethanol (Sigma, Thermo Scientific, Rockford, 
IL). Samples were subjected to SDS-PAGE on 7% gels, and the gels were either stained for 
mass spectrometry identification (described below) or transferred to PVDF membranes for 
immunoblotting. Non-specific binding was determined by performing parallel 
immunoprecipitation with mouse or rabbit IgG in each experiment. In preliminary 
experiments, the production of IIbR858G/R859G and 3 was confirmed in the transfected 
HEK293 cell line by immunoprecipitation with both anti-IIb and anti-3 mAbs followed by 
immunoblot. For biosynthetic labeling, cells were incubated for 30 min at 37°C in 
methionine/cysteine-free medium, followed by pulse-labeling for 15 min at 37ºC in medium 
containing 35S-methionine/cysteine (300 Ci/10 cm plate). The pulse was terminated by 
incubation in medium containing unlabeled methionine/cysteine (1 mg/ml each) and the 
cells were incubated at 37 °C until lysis in 1% Triton-X 100 lysis buffer. Following cell lysis, 
supernatants were prepared as above. Gels were dried and exposed to film. For inhibition of 
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the proteasome cells were incubated in the proteasome inhibitor MG132 (10 
M)(Sigma_Aldrich, St Louis, MO) in normal growth medium at 37C and then immediately 
lysed. 
2.5 Histidine-tag/Nickel bead pulldown assay  
HEK293 cells expressing poly-histidine tagged IIb cDNA (in vector pEF1/V5-His) and 3 
cDNA (in vector pcDNA3.1)(Mitchell, Li et al. 2007) were lysed in 1% Triton, 150 mM NaCl, 
10 mM imidazole buffer (lysis buffer) on ice for 30 m, centrifuged for 30m at 4C, and then 
the supernatant was reacted with 50 l of a 6:4 slurry of Ni beads:imidazole buffer (Qiagen, 
Inc. Valencia, CA) to bind the histidine-tagged subunits to the nickel beads. After incubating 
for 30 m the beads were washed four times with 10 mM imidazole lysis buffer by using a 
magnetic chamber to isolate the beads. Next, fresh whole cell lysates (1 mL) of UCB-derived 
megakaryocytes in 1% Triton, 150 mM NaCl, 10 mM imidazole buffer were incubated with 
the washed, Ni-bound IIb for 1 h, and then the beads were washed twice with 1 mL lysis 
buffer containing 20 mM imidazole. Ni-bound proteins were eluted with 250 mM imidazole 
and the entire eluate was subjected to SDS-PAGE on a 7% gel followed by staining with 
Imperial Stain (Pierce, Thermo Scientific, Rockford, IL). Control experiments were run in 
parallel in which no megakaryocyte lysate was added to the beads, but all other steps 
remained the same. These controls aimed to identify the remaining HEK293 cell proteins 
still bound to either the beads or to IIb after the washing steps, before incubation with 
megakaryocyte lysate. Experimental and control gels were run simultaneously, and the 
lanes were excised and analyzed by mass spectrometry.  
2.6 Photocrosslinking amino acids 
UCB cells were cultured as described above for eight days, then were washed and incubated 
for 24 hours in leucine- and methionine- free medium containing photoreactive methionine 
and leucine, dialyzed FBS (both Pierce, Thermo Scientific, Rockford, IL), and 50 ng/ml TPO 
(Millipore, Temecula,CA). The cells were exposed to 345 nm UV light for 15 minutes to 
crosslink the photoreactive amino acids, and harvested immediately, according to 
manufacturer’s instructions. Whole cell lysates were immunoprecipitated with antibodies 
specific for IIb or 3, and the proteins were separated by SDS-PAGE using the same 
protocol as for the histidine-tag affinity capture. Controls were simultaneously 
immunoprecipitated with non-immune IgG. Experimental and control lanes were excised 
and analyzed by mass spectrometry. 
2.7 RNAi  
HEK293 cells stably expressing high levels of IIb and 3 were transfected with 100 nM 
siRNA duplexes (Dharmacon, Thermo Scientific, Rockford, IL and Qiagen, Valencia, CA) 
using Dharmafect-1 reagent (Dharmacon, Thermo Scientific, Rockford, IL), then analyzed by 
flow cytometry using a FacsCanto (Becton Dickenson, ) at 48-96 h after transfection. 
Cultured UCB cells were transfected twice, on culture days 3 and 5, with 100 nM of siRNA 
duplexes or controls also using Dharmafect-1 reagent, and then analyzed 48 – 72 h later by 
flow cytometry. In order to identify individual transfected cells by FACS, cells were co-
transfected with 10 nM of fluorescent-labeled non-coding siRNA (Qiagen, Valencia, CA). In 
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some experiments, Cy3-labeled siRNA duplexes were used (Dharmacon, Thermo Scientific, 
Rockford, IL). Controls were: no treatment, transfection reagent but no siRNA duplex, Cy3-
labeled negative control siRNA duplex only (Qiagen), siControl non targeting siRNA 
duplex, and siRNA duplex against cyclophillin B (positive control) (both Dharmacon). 
2.8 Quantitative RT-PCR 
For analysis of RNA content, cells were collected in RNAlater (Applied Biosystems, Foster 
City, CA) and RNA was purified using the RNEasy mini kit (Qiagen, Valencia, CA). For 
some analyses, siRNA transfected cells were sorted for expression of the fluorescent marker 
using a MoFlo sorter, and the sorted cells were subjected to QRT-PCR. Analysis was 
performed on an ABI 7900 or an ABI 7700 thermocycler/ fluorescence analyzer (Applied 
Biosystems, Foster City, CA) using the SYBR green probe (Qiagen or Invitrogen) and 
Quantitect primer assays (Qiagen). Relative mRNA levels were calculated using the Ct 
method that corrects for GAPDH expression in all samples. Fold-reduction was corrected for 
percent transfection in each experiment. 
2.9 Immunofluorescence analysis 
Mks were cytospun onto poly L-lysine-coated glass coverslips and fixed in methanol for 5 
minutes at RT. Cells were then washed with saponin buffer (PBS containing 0.02% BSA, 
0.005% saponin), then blocked with saponin buffer for 1 hour at RT. Cells were then 
incubated with the primary antibody diluted in saponin buffer for 1 hour at RT. After 
washing with PBS, cells were incubated with the appropriate conjugated secondary 
antibody in PBS for 1 hour at RT. Specimens were mounted with Prolong gold (Invitrogen). 
Images were acquired using a Zeiss LSM 510 META (Axiovert 200M Inverted Microscope 
Stand) confocal laser scanning microsope through a 100x objective. Each set of staining 
conditions was repeated 3 times. Background fluorescence was measured by incubating 
fixed cells with the secondary antibody only and then acquiring images with the exact 
settings used to obtain the experimental images. 
2.10 Mass spectrometry data analysis 
The protein gel bands were excised from the SDS-PAGE. The gel bands were reduced with 
10 mM of DTT and alkylated with 55 mM iodoacetamide, and then digested with Sequence 
Grade Modified Trypsin (Promega, Madison, Wisconsin) in ammonium bicarbonate buffer 
at 37 overnight.(Kumarathasan, Mohottalage et al. 2005) The digestion products were 
extracted twice with 0.1% trifluoroacetic acid and 50% Acetonitrile and 1.0% trifluoroacetic 
acid respectively. The extracted mixture was dried by Speed-Vac and redisolved in 10 L 
0.1% trifluoroacetic acid. Half of the extracts were injected by LC-MS/MS analysis. For LC-
MS/MS analysis, each digestion product was separated by a 60 min gradient elution with 
the Dionex U3000 capillary/nano-HPLC system (Dionex, Sunnyvale, California) at a flow 
rate of 0.250 L/min that is directly interfaced with the Thermo-Fisher LTQ-Obritrap mass 
spectrometer (Thermo Fisher, San Jose, California) operated in data-dependent scan mode. 
The analytical column was a home-made fused silica capillary column (75 m ID, 100 mm 
length; Upchurch, Oak Harbor, Washington) packed with C-18 resin (300 A, 5 m, Varian, 
Palo Alto, California). Mobile phase A consisted of 0.1% formic acid, and mobile phase B 
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consisted of 100% acetonitrile and 0.1% formic acid. The 60 min gradients with 250 nL/min 
flow rate for B solvent went from 0 to 55% in 34 minutes and then in 4 min to 80%. The B 
solvent stayed at 80% for another 8 min and then decreased to 5% in 8 min. Another 6 min 
was used for equilibration, loading and washing. The mass acquisition method was one FT-
MS scan followed by 6 subsequent MS/MS scan in the ion trap. The FT-MS scan was 
acquired at resolution 30,000 in the Orbi-trap. The six most intense peaks from the FT full 
scan were selected in the ion trap for MS/MS. The selected ions were excluded for further 
selection for 180 seconds. The following search parameters were used in all MASCOT 
searches: maximum of 1 missed trypsin cleavages, cysteine carbamidomethylation, 
methionine oxidation. The maximum error tolerance for MS scans was 10 ppm for MS and 
1.0 Da for MS/MS respectively. Proteins were designated as “hits” if they matched at least 2 
distinctive peptides with a MASCOT score of at least 40. For proteins matching the same 
sets of peptides, only the protein with the greater percentage of coverage was selected. In 
the one case where 2 isoforms could not be distinguished (HSP70A/B), both proteins are 
reported. Proteins identified in the control gels were considered “negative,” and these 
proteins were removed from further analysis. The interaction data were further analyzed 
using the Cytoscape(Cline, Smoot et al. 2007) software and publically available protein 
interaction databases (e.g. INTACT, NCBI, UniProt) to generate a network of first-degree 
interactions with IIb. The network was further expanded to include proteins that were 
previously reported to interact with IIb and known interactions between any of the 
proteins identified in our primary assays.  
2.11 Statistical analysis 
Flow cytometry data was summarized as the geographic mean fluorescence intensity (MFI) 
of antibody binding, and normalized to the MFI of control siRNA treated cells, so that the 
experimental MFI is expressed as a percentage of the control MFI. The overall percent 
change of the replicates was expressed as the average percent change +/- the confidence 
interval. The two-sided, paired t-test was used to determine whether there were differences 
in antibody binding between the different experimental groups. In the siRNA experiments, 
relative mRNA levels were calculated using the Ct method that corrects for GAPDH 
expression.  
3. Results 
3.1 The IIb interactome 
Proteins putatively interacting with IIb were isolated from UCB derived megakaryocytes 
and from HEK293 cells expressing IIb3, and these proteins were analyzed by mass 
spectrometry. Samples were processed by the two methods depicted in Figure 2. In the first 
method, recombinant IIb or IIbR858G/R859G subunits bearing a polyhistidine tag were 
expressed in HEK293 cells along with normal 3. The cells were lysed with 1% Triton buffer, 
and the lysates were reacted with Ni beads that bind polyhistidine. The Ni beads were 
washed using a magnetic separator to reduce non-specific binding to the Ni-bound IIb, 
and then incubated with fresh whole cell lysate of umbilical cord blood derived 
megakaryocyte. Since we are interested in the early process of IIb3 formation and 
intracellular trafficking we used megakaryocytes at day 8 or 9 of culture; at that point in our 
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system IIb3 is highly expressed but there is not yet any proplatelet formation. The Ni-
bound histidine-tagged IIb and IIb-bound proteins were washed twice and then were 
eluted from the Ni beads with 250 mM imidazole in a 1% Triton buffer. Simultaneous 
control experiments were performed without megakaryocyte lysate in order to identify 
proteins non-specifically binding to either the Ni beads or the polyhistidine tag. The 
proteins thus collected were separated by one dimensional SDS-PAGE on a 7% gel. After 
staining, the experimental and control lanes were cut out and analyzed by mass 
spectrometry. This entire process was repeated in three separate experiments with normal 
IIb, and in four separate experiments with IIbR858G/R859G. 
 
Fig. 2. Methods used to isolate and identify IIb-interacting proteins. A): Polyhistidine-
tagged IIb subunits were captured on Ni beads and then incubated with whole cell lysate 
of day 8 UCB-derived megakaryocytes. Protein complexes thus captured were processed as 
described in the text, and then the proteins were identified by FT-MS and MS/MS. B) 
Crosslinking experiments were performed on day 8 UCB-derived megakaryocytes and 
transfected HEK293 cells. Cells were fed photoactivatable methionine and leucine, exposed 
to UV light and lysed immediately. Samples were processed for mass spectrometry as 
described. 
The second strategy used photo-activated amino acids to crosslink IIb to its binding 
partners (Figure 2B). UCB-derived megakaryocytes were starved for methionine and 
leucine, then fed photo-activatable methionine and leucine overnight, and then exposed to 
UV light to crosslink the amino acids of neighboring proteins. The megakaryocytes were 
immediately lysed and the IIb-bound proteins were immunoprecipitated by anti-IIb 
mAb. These proteins were separated by one dimensional SDS-PAGE and then the 
appropriate bands were cut out and analyzed by mass spectrometry. Because we were 
looking only for proteins crosslinked to IIb, only the portions of the bands with Mr > 120 
(Mr of the mature IIb subunit) were analyzed. Five separate crosslinking experiments were 
performed with UCB-derived megakaryocytes and two on HEK293 cells expressing 
IIbR858G/R859G and normal 3. 
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Minimum criteria for protein inclusion in data analysis were at least 2 distinctive peptides 
with a MASCOT score of at least 40, and absence of the protein in the control lanes. 
Importantly, since we were interested in proteins that are more abundant in the 
megakaryocyte than in HEK293 cells, even proteins known to interact with IIb3, such as 
talin, were removed from the final results because they were present in the control lanes. 
Proteins identified in the Ni bead extraction experiments that are known to harbor natural 
polyhistidine sequences (such as the DEAH boxes) that could independently bind to the Ni 
beads were also excluded. Combining the results of both methods, 98 proteins were 
identified as potentially interacting with the normal IIb subunit, and 79 proteins were 
identified as putatively interacting with the IIbR858G/R859G subunit (Table 1). These 163 
proteins putatively constitute a portion of the IIb interactome, a network of protein-protein 
interactions relevant to the trafficking and function of IIb in megakaryocytes (Figure 3).  
 
Proteins Captured with IIbR858G/R859G 
Gene 
Symbol 
Entrez 
Gene ID
SwissProt 
Acc No. 
Protein Acc No. Description # Pep 
% 
Cov 
#. 
Expt 
MYH9 4627 
P35579 
Q60FE2   gi|12667788  
MYOSIN, HEAVY 
POLYPEPTIDE 9, NON-
MUSCLE 70 45 4 
LMNA 4000 P02545    gi|5031875  LAMIN A/C 37 61 3 
HNRNPL* 3191 
P14866 
A6NIT8 
Q6NTA2  gi|11527777 
HETEROGENEOUS 
NUCLEAR 
RIBONUCLEOPROTEIN L 33 53 4 
STIM1 6786 Q13586    gi|21070997  
STROMAL INTERACTION 
MOLECULE 1 28 46 2 
CKAP4 10970 Q07065    gi|19920317  
CYTOSKELETON-
ASSOCIATED PROTEIN 4 27 55 2 
HSP90AB1 3326 P08238    gi|154146191  
HEAT SHOCK PROTEIN 
90kDa ALPHA, CLASS A 
MEMBER 1 21 36 1 
SF3A1 10291 Q15459     gi|53831995  
SPLICING FACTOR 3A, 
SUBUNIT 1, 120kDa 16 32 1 
HSPA1A* 3303 
B3KTT5 
P08107 
A8K5I0  gi|5123454  
HEAT SHOCK 70kDa 
PROTEIN 1A 15 34 3 
ATXN2L* 11273 
Q8WWM7 
A8K1R6   gi|119572372  ATAXIN 2-LIKE 14 20 2 
MYH10 4628 
Q6PK16 
P35580 
Q9BWG0  gi|41406064  
MYOSIN, HEAVY 
POLYPEPTIDE 10, NON-
MUSCLE 13 9 1 
DNAJC10* 54431 Q8IXB1    gi|24308127  
DNAJ (HSP40) HOMOLOG, 
SUBFAMILY C, MEMBER 10 13 21 3 
PSPC1 55269 Q8WXF1   gi|109240550  
PARASPECKLE 
COMPONENT 1 13 35 3 
SFPQ 6421 
P23246 
Q86VG2   gi|119627829  
SPLICING FACTOR 
PROLINE/GLUTAMINE-
RICH (POLYPYRIMIDINE 
TRACT BINDING PROTEIN 
ASSOCIATED) 12 35 1 
SF1* 7536 Q14820 gi|42544123  SPLICING FACTOR 1 12 20 2 
www.intechopen.com
 Hematology – Science and Practice 
 
180 
Q15637   
HSPA5* 3309 P11021    gi|119608027  
HEAT SHOCK 70kDa 
PROTEIN 5 (GLUCOSE-
REGULATED PROTEIN, 
78kDa) 11 37 4 
HLF2 4057 P02788    gi|16198357  LACTOTRANSFERRIN 11 30 1 
MYH11 4629 
P35749 
Q3MNF1 
Q3MIV8 
Q3MNF0 gi|119574312  
MYOSIN, HEAVY 
POLYPEPTIDE 11 11 9 1 
LTBP1 4052 
Q14766 
B7ZLY3   gi|46249414  
LATENT TRANSFORMING 
GROWTH FACTOR BETA 
BINDING PROTEIN 1 10 8 2 
PKM2* 5315 P14618    gi|127795697  
PYRUVATE KINASE, 
MUSCLE 10 28 1 
RAVER1* 125950 Q8IY67    gi|123173757  RAVER1 10 29 2 
XIRP2 129446 A4UGR9   gi|61696134 
CARDIOMYOPATHY 
ASSOCIATED 3 10 16 1 
ABCF1 23 
Q8NE71 
Q2L6I2 
A2BF75  gi|21759807  
ATP-BINDING CASSETTE, 
SUB-FAMILY F (GCN20), 
MEMBER 1 9 14 1 
POTEF 728378 A5A3E0    gi|153791352 
POTE ANKYRIN DOMAIN 
FAMILY, F 9 8 1 
HSP90AA1 3320 
P07900 
Q86SX1   gi|153792590  
HEAT SHOCK PROTEIN 
90kDa ALPHA, CLASS A 
MEMBER 1 8 13 3 
ITGA2B* 3674 P08514    gi|119571981  
INTEGRIN, ALPHA 2B 
(PLATELET GLYCOPROTEIN 
IIB OF IIB/IIIA COMPLEX, 
ANTIGEN CD41) 8 17 2 
TF* 7018 
Q06AH7 
P02787   gi|110590597  TRANSFERRIN 8 18 2 
SAP 62 8175 A0PJA6    gi|21361376  
SPLICING FACTOR 3A, 
SUBUNIT 2, 66kDa 8 19 1 
LYZ 4069 
Q05DF2 
Q15428   gi|4930023  
LYSOZYME (RENAL 
AMYLOIDOSIS) 7 70 1 
SMAD4 4089 
P61626 
B2R4C5 
Q13485   gi|4885457  
SMAD, MOTHERS AGAINST 
DPP HOMOLOG 4 
(DROSOPHILA) 7 12 2 
HSP90B1 7184 P14625    gi|4507677  
HEAT SHOCK PROTEIN 
90kDa BETA (GRP94), 
MEMBER 1 7 12 2 
CANX 821 P27824    gi|10716563  CALNEXIN 6 13 1 
LRP2 4036 
Q7Z5C1 
P98164 
Q7Z5C0  gi|32816595 
LOW DENSITY 
LIPOPROTEIN-RELATED 
PROTEIN 2 6 1 1 
CCT3 7203 
A6NE14 
P49368 
B3KX11   gi|14124984  
CHAPERONIN 
CONTAINING TCP1, 
SUBUNIT 3 (GAMMA) 6 21 2 
HSPA1L 3305 P34931    gi|21759781  
HEAT SHOCK 70kDa 
PROTEIN 1-LIKE 5 15 2 
NCL 4691 P19338 gi|189306  NUCLEOLIN 5 6 1 
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B3KM80   
PIP 5304 P12273    gi|4505821  
PROLACTIN-INDUCED 
PROTEIN 5 31 1 
SLPI 6590 P03973    gi|4507065  
SECRETORY LEUKOCYTE 
PEPTIDASE INHIBITOR 5 28 1 
TPM1 7168 
P09493 
Q9Y427 
O15513  gi|854189  TROPOMYOSIN 1 (ALPHA) 5 10 1 
HECTD1 25831 Q9ULT8    gi|118498337  
HECT DOMAIN 
CONTAINING 1 5 5 3 
LACRT 90070 Q9GZZ8   gi|15187164  LACRITIN 5 30 1 
ACTG3 71 P63261    gi|178045   4 12 1 
DMBT1 1755 Q9UGM3   gi|169218264  
DELETED IN MALIGNANT 
BRAIN TUMORS 1 4 11 1 
FLG 2312 P20930    gi|62122917  FILAGGRIN 4 2 1 
HNRNPK 3190 
P61978 
Q6IBN1   gi|55958544  
HETEROGENEOUS 
NUCLEAR 
RIBONUCLEOPROTEIN K  4 11 2 
HSPA8* 3312 
B3KTV0 
P11142   gi|5729877  
HEAT SHOCK 70kDa 
PROTEIN 8 4 8 1 
KPNB1 3837 Q14974    gi|119615215  
KARYOPHERIN (IMPORTIN) 
BETA 1 4 8 1 
LCN1 3933 P31025    gi|4504963  LIPOCALIN 1 4 30 1 
LMAN1* 3998 P49257    gi|5031873  
LECTIN, MANNOSE-
BINDING, 1 4 15 1 
PRSS2 5645 
P07478 
Q5NV56   gi|74353564  
PROTEASE, SERINE, 2 
(TRYPSIN 2) 4 15 1 
ALDH18A1  5832 P54886    gi|76779856  
ALDEHYDE 
DEHYDROGENASE 18 
FAMILY, MEMBER A1 4 5 1 
NPM3 10360 O75607    gi|5801867 
NUCLEOPHOSMIN/NUCLE
OPLASMIN, 3 4 12 1 
WAC 51322 Q9BTA9    gi|55664165  
WW DOMAIN CONTAINING 
ADAPTOR WITH COILED-
COIL 4 5 1 
ANKRD24 170961 Q8TF*21   gi|16418357  
ANKYRIN REPEAT DOMAIN 
24 4 5 1 
CALM1 801 
Q96HY3 
P62158 
B4DJ51  gi|61680528 CALMODULIN 3 18 1 
COL7A1 1294 
Q02388 
Q59F16   gi|119585300  
COLLAGEN, TYPE VII, 
ALPHA 1 (EPIDERMOLYSIS 
BULLOSA, DYSTROPHIC, 
DOMINANT AND 
RECESSIVE) 3 1 1 
HSPD1 3329 P10809    gi|14326412  
HEAT SHOCK 60kDa 
PROTEIN 1 3 15 2 
ME2 4200 
P23368 
Q9BWL6   gi|5822326  
MALIC ENZYME 2, NAD(+)-
DEPENDENT 3 5 2 
PEX1 5189 O43933     gi|4505725 
PEROXISOMAL BIOGENESIS 
FACTOR 1 3 2 1 
PRKAA1 5562 Q13131    gi|29124503  
PROTEIN KINASE, AMP-
ACTIVATED, ALPHA 1 3 5 1 
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CATALYTIC SUBUNIT
H6PD 9563 O95479    gi|51859374  
HEXOSE-6-PHOSPHATE 
DEHYDROGENASE 
(GLUCOSE 1-
DEHYDROGENASE) 3 3 2 
PDIA4 9601 
Q549T6 
P13667   gi|37182276  
PROTEIN DISULFIDE 
ISOMERASE FAMILY A, 
MEMBER 4 3 2 1 
COLEC10 10584 Q9Y6Z7    gi|5453619  
COLLECTIN SUB-FAMILY 
MEMBER 10 (C-TYPE 
LECTIN) 3 12 1 
FOXJ3 22887  gi|114555879  FORKHEAD BOX J3 3 4 1 
ARS2 51593 Q9BXP5    gi|33150698 ARS2 PROTEIN 3 5 1 
FOXJ2 55810 Q9P0K8    gi|8923842  FORKHEAD BOX J2 3 4 1 
UBAP2 55833 
Q5T6F2 
Q9P0H6   gi|22325364  
UBIQUITIN ASSOCIATED 
PROTEIN 2 3 3 1 
KIAA1529* 57653 Q9P1Z9    gi|7959325  KIAA1529 3 2 3 
LRRC8E 80131 B3KR78    gi|801893  
LEUCINE RICH REPEAT 
CONTAINING 8 FAMILY, 
MEMBER E 3 3 1 
QRICH2 84074 Q9H0J4    gi|14149793  GLUTAMINE RICH 2 3 3 1 
DPP9* 91039 
Q86TI2 
Q1ZZB8   gi|119589606  DIPEPTIDYL-PEPTIDASE 9 3 4 2 
LPLUNC1 92747 Q8TDL5     gi|40807482 
NASOPHARGYNEAL 
RELATED 3 6 1 
DOK7 285489 Q18PE1    gi|119602869  
HYPOTHETICAL PROTEIN 
FLJ33718 3 4 1 
SLFN14 342618 P0C7P3    gi|193788704 
ORTHOLOG OF MOUSE 
SCHLAFEN 10 3 5 1 
ENO1 2023 P06733    gi|4503571  ENOLASE 1 2 6 1 
XRCC5 7520 P13010    gi|119590969  
X-RAY REPAIR 
COMPLEMENTING 
DEFECTIVE REPAIR IN 
CHINESE HAMSTER CELLS 5 
(DOUBLE-STRAND-BREAK 
REJOINING; KU 
AUTOANTIGEN, 80kDa) 2 4 1 
WDR1 9948 O75083    gi|12652891  WD REPEAT DOMAIN 1 2 6 1 
NLRP1 22861 
Q9C000 
Q9H5Z7   gi|37927559  
NLR FAMILY, PYRIN 
DOMAIN CONTAINING 1 2 1 1 
PPA2 27068 
Q9H2U2 
A6NKL9   gi|119612395  
PYROPHOSPHATASE 
(INORGANIC) 2 2 1 1 
VPS35 55737 Q96QK1   gi|7022978 
VACUOLAR PROTEIN 
SORTING 35 2 2 1 
 
Proteins Captured with normal IIb 
Gene Symbol 
Entrez
Gene ID
SwissProt 
Acc No. 
Protein Acc 
No. 
Description # Pep % Cov # Exp 
ITGB3* 3690 P05106  gi|183531 
INTEGRIN, BETA 3 
(PLATELET 
GLYCOPROTEIN IIIA, 
ANTIGEN CD61) 25 42 7 
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TUBB2C 7284 P49411  gi|20809886  TUBULIN, BETA 2C 17 35 1 
DHTKD1 55526 Q96HY7 gi|119606733 
DEHYDROGENASE E1 AND 
TRANSKETOLASE 
DOMAIN CONTAINING 1 15 36 1 
GLUD1 2746 P00367  gi|183056 
GLUTAMATE 
DEHYDROGENASE 1 15 67 3 
DARS 1615 
P14868 
P78371  gi|45439306 
ASPARTYL-TRNA 
SYNTHETASE 14 60 3 
LMAN1* 3998 P49257  gi|5031873  
LECTIN, MANNOSE-
BINDING, 1 12 36 1 
PRKAB1 5564 Q9Y478  gi|4506061  
PROTEIN KINASE, AMP-
ACTIVATED, BETA 1 NON-
CATALYTIC SUBUNIT 12 38 1 
HSPA5* 3309 
P11021 
P08246  gi|16507237  
HEAT SHOCK 70kDa 
PROTEIN 5 (GLUCOSE-
REGULATED PROTEIN, 
78kDa) 11 30 1 
SCN10A 6336 
P43626 
P43628 
P43632  gi|110835709
SODIUM CHANNEL, 
VOLTAGE-GATED, TYPE X, 
ALPHA 11 5 1 
TUBB 10383 P68371  gi|7106439 TUBULIN, BETA 5 11 44 4 
TUBB4 23071 Q9BS26  gi|21361322  TUBULIN, BETA 4 10 26 1 
ALDH18A1 5832 P54886  gi|76779856  
ALDEHYDE 
DEHYDROGENASE 18 
FAMILY, MEMBER A1 9 18 2 
DNAJC10* 54431 Q8IXB1  gi|24308127  
DNAJ (HSP40) HOMOLOG, 
SUBFAMILY C, MEMBER 10 9 21 4 
EXOSC10 5394 
Q01780 
P05156  gi|50301239 
EXOSOME COMPONTENT 
10 9 8 1 
UGP1 10352 Q9UGM6  gi|48255966  
UDP-GLUCOSE 
PYROPHOSPHORYLASE 1 9 33 1 
ADPGK 83440 Q9BRR6  gi|31542509  
ADP-DEPENDENT 
GLUCOKINASE 8 22 1 
ALAD 210 P13716  gi|248839  
AMINOLEVULINATE, 
DELTA-, DEHYDRATASE 8 22 1 
CCT2 10576 P78371  gi|5453603  
CHAPERONIN 
CONTAINING TCP1, 
SUBUNIT 2 (BETA) 8 39 1 
CCT4 10575 P50991  gi|38455427  
CHAPERONIN 
CONTAINING TCP1, 
SUBUNIT 4 (DELTA) 8 28 1 
FARS2 10667 O95363  gi|62898407  
PHENYLALANINE-TRNA 
SYNTHETASE 2  8 24 1 
HSPA1A* 3303 B3KTT5 gi|5123454  
HEAT SHOCK 70kDa 
PROTEIN 1A 8 19 1 
HSPA1B 3304 P08107  gi|167466173 
HEAT SHOCK 70kDa 
PROTEIN 1B 8 21 1 
HSPA9 3313 P38646  gi|12653415  
HEAT SHOCK 70kDa 
PROTEIN 9B (MORTALIN-2) 8 17 2 
NUDT19 390916 A8MXV4 gi|157739940 
NUDIX (NUCLEOSIDE 
DIPHOSPHATE LINKED 
MOIETY X)-TYPE MOTIF 19 8 36 1 
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AKR7A2 8574 O43488  gi|41327764  
ALDO-KETO REDUCTASE 
FAMILY 7, MEMBER A2 
(AFLATOXIN ALDEHYDE 
REDUCTASE) 7 37 1 
CHD9 80205 Q3L8U1 gi|95147342 
CHROMODOMAIN 
HELICASE DNA BINDING 
PROTEIN 9 7 2 1 
FAM175B 23172  gi|148529023
UNKNOWN PROTEIN 
LOC23172 7 14 1 
KIF14 9928 Q15058  gi|7661878 
KINESIN FAMILY MEMBER 
14 7 4 1 
NT5DC2 22978 A8K6K2 gi|12597653  
5'-NUCLEOTIDASE 
DOMAIN CONTAINING 2 7 36 2 
P15RS 55197 Q96P16 gi|142385371
REGULATION OF 
NUCLEAR pre-mRNA 
DOMAIN CONTAINING 1A 7 20 1 
PDLIM1 9260 
Q9Y3C6 
Q9NR12  gi|13994151  
PDZ AND LIM DOMAIN 1 
(ENIGMA) 7 37 1 
PM20D2 135293 Q8IYS1  gi|58082085  AMINOACYLASE 1-LIKE 2 7 15 1 
POLDIP2 26073 
Q9Y2S7 
Q9BVV8  gi|7661672  
POLYMERASE (DNA-
DIRECTED), DELTA 
INTERACTING PROTEIN 2 7 26 1 
TF* 7018 P02787  gi|553788  TRANSFERRIN 7 12 1 
ACTN4 604638  gi|2804273  ACTININ, ALPHA 4 6 9 1 
ATXN2L* 11273 Q8WWM7 gi|119572372 ATAXIN 2-LIKE 6 9 1 
CCT7 10574 Q99832  gi|62896515  
CHAPERONIN 
CONTAINING TCP1, 
SUBUNIT 7 (ETA) 6 23 1 
CNDP2 55748 Q96KP4  gi|8922698 
CNDP DIPEPTIDASE 2 
(METALLOPEPTIDASE M20 
FAMILY) 6 11 1 
FLJ12529 79869 Q8N684  gi|24432016  
PRE-MRNA CLEAVAGE 
FACTOR I, 59 kDa SUBUNIT 6 12 1 
PBEF1 10135 P43490   gi|55960735 
PRE-B-CELL COLONY 
ENHANCING FACTOR 1 6 4 1 
PPP1R9A 55607 Q9ULJ8  gi|261244899
PROTEIN PHOSPHATASE 1, 
REGULATORY (INHIBITOR) 
SUBUNIT 9A, 5 isoforms 6 5 1 
RB1CC1 9821 Q8TDY2  gi|134304845
RB1-INDUCIBLE COILED-
COIL 1 6 3 1 
SERBP1 26135 
Q8NC51 
Q9H707  gi|66346679  
SERPINE1 MRNA BINDING 
PROTEIN 1 6 16 1 
TXNDC4 23352 
Q8WXW3 
Q5T4S7  gi|119579327 
THIOREDOXIN DOMAIN 
CONTAINING 4 
(ENDOPLASMIC 
RETICULUM) 6 35 3 
ACLY 47 
Q9NP58 
P53396  gi|38569423  ATP CITRATE LYASE 5 3 1 
ACTB 60 Q1KLZ0 gi|14250401 ACTIN, BETA 5 22 3 
CTTN 2017  gi|2498954  CORTACTIN 5 4 1 
CUL-5 8065 Q93034  gi|67514034 CULLIN 5 5 5 1 
FHL1 2273 Q13642  gi|3851650  FOUR AND A HALF LIM 5 3 1 
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DOMAINS 1 
GPHN 10243 Q9NQX3  gi|10880983  GEPHYRIN ISOFORM 1 5 8 1 
HNRPH1 3187 P31943  gi|5031753  
HETEROGENEOUS 
NUCLEAR 
RIBONUCLEOPROTEIN H1 5 16 1 
HSPA8* 3312 P11142  gi|10880983  
HEAT SHOCK 70kDa 
PROTEIN 8 5 8 3 
IDH3A 3419 P50213  gi|5031777  
ISOCITRATE 
DEHYDROGENASE 3 
(NAD+) ALPHA 5 13 1 
PRKAG1 5571 P54619  gi|2230863  
PROTEIN KINASE, AMP-
ACTIVATED, GAMMA 1 
NON-CATALYTIC SUBUNIT 5 27 1 
RILPL1 353116 Q5EBL4 gi|30315660  
RAB INTERACTING 
LYSOSOMAL PROTEIN-
LIKE 1 5 12 1 
SAP130 79595 Q9H0E3  gi:25579126 
SIN3A-ASSOCIATED 
PROTEIN, 130kDa 5 3 1 
WARS2 80139 Q9H7S9  gi|7710154  
TRYPTOPHANYL TRNA 
SYNTHETASE 2 5 19 1 
ADCY6 112 O43306  gi|168480141 ADENYLATE CYCLASE 6 4 3 1 
C5orf25 375484 Q8NDZ2  gi|196259795 FLJ44216 PROTEIN 4 8 1 
CARS2 79587 Q9HA77 gi|119618821 
HYPOTHETICAL PROTEIN 
FLJ39378 4 10 1 
CIT 11113 O14578  gi|32698687 
CITRON (RHO-
INTERACTING, 
SERINE/THREONINE 
KINASE 21) 4 2 1 
EEF2K 29904 O00418  gi|9558749  
EUKARYOTIC 
ELONGATION FACTOR-2 
KINASE 4 4 1 
FLJ22184 80164 Q9H6K5 gi|239757129
HYPOTHETICAL PROTEIN 
FLJ22184 4 5 1 
FLNA 2316 P21333  gi|57284166  
FILAMIN A, ALPHA 
(ACTIN BINDING PROTEIN 
280) 4 2 2 
FRMPD1 22844 Q5SYB0 gi|239582740
FERM AND PDZ DOMAIN 
CONTAINING 1 4 3 1 
GOPC 57120 Q9HD26  gi|9966877  
GOLGI ASSOCIATED PDZ 
AND COILED-COIL MOTIF 
CONTAINING 4 12 1 
HMGCS1 3157 Q01581  gi|53734504  
3-HYDROXY-3-
METHYLGLUTARYL-
COENZYME A SYNTHASE 1 
(SOLUBLE) 4 14 1 
HNRNPL* 3191 P14866  gi|133274  
HETEROGENEOUS 
NUCLEAR 
RIBONUCLEOPROTEIN L 4 11 2 
HTRA2 27429 O43464  gi|21614538  HTRA SERINE PEPTIDASE 2 4 16 1 
NAGK 55577 Q9UJ70  gi|6491737  
N-ACETYLGLUCOSAMINE 
KINASE 4 10 1 
PKM2* 5315 P14618  gi|31416989  PYRUVATE KINASE, 4 16 1 
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MUSCLE 
PRDX3 10935 
Q05940 
P30048  gi|14250063  PEROXIREDOXIN 3 4 20 1 
SF1* 7536 Q15637  gi|46362557  SPLICING FACTOR 1 4 5 1 
TIMM50 92609 Q3ZCQ8  gi|48526509  
TRANSLOCASE OF INNER 
MITOCHONDRIAL 
MEMBRANE 50 HOMOLOG 4 6 1 
AER61 285203  gi|39930530 
GLUCOSYLTRANSFERASE 
AER61 C3orf64 3 6 1 
CSNK2A2 1459 Q14012  gi|4503097  
CASEIN KINASE 2, ALPHA 
PRIME POLYPEPTIDE 3 6 1 
DPP9* 91039 Q86TI2  gi|114657671 DIPEPTIDYL-PEPTIDASE 9 3 2 1 
DVL2 1856 O14641  gi|55665917  
DISHEVELLED, DSH 
HOMOLOG 2 
(DROSOPHILA) 3 2 1 
ELMO1 9844 O60895  gi|86788139 
ENGULFMENT AND CELL 
MOTILITY 1 3 5 1 
GAPDH 2597 
P04406 
Q16678  gi|31645  
GLYCERALDEHYDE-3-
PHOSPHATE 
DEHYDROGENASE 3 18 1 
KIAA0895 23366 Q8NCT3 gi|154426319 KIAA0895 PROTEIN 3 6 1 
LUC7L2 51631 Q9Y383  gi|4929587  CGI-59 PROTEIN 3 5 1 
MPO 4353 P05164  gi|88180  MYELOPEROXIDASE 3 5 2 
PEG10 23089 Q86TG7 gi|94421473  
PATERNALLY EXPRESSED 
10 3 11 1 
RPLP0 6175 
P05388 
Q9NQX7  gi|12654583  
RIBOSOMAL PROTEIN, 
LARGE, P0 3 12 1 
SEC13 6396 A8MV37 gi|119584482 
SEC13-LIKE 1 (S. 
CEREVISIAE) 3 11 1 
SEC23A 10484 
Q15436 
Q92736  gi|22477159  
SEC23 HOMOLOG A (S. 
CEREVISIAE) 3 3 1 
SHROOM3 57619 Q8TF72  gi|57284166  
SHROOM3 F-ACTIN 
BINDING PROTEIN 3 2 4 
UBR4 23352  gi|9367763  ZINC FINGER, UBR1 TYPE 1 3 3 1 
A2M 2 P01023  gi|177872  
ALPHA-2-
MACROGLOBULIN 2 1 1 
ABCA13 154664 Q86UQ4  gi|8928549  
ATP-BINDING CASSETTE, 
SUB-FAMILY A (ABC1), 
MEMBER 13 2 5 2 
CORO1A 11151 P31146  gi|5902134  
CORONIN, ACTIN 
BINDING PROTEIN, 1A 2 4 1 
KIAA1529* 57653 Q9P1Z9 gi|7959325 KIAA1529 2 2 4 
MAP3K7IP2 23118 Q9NYJ8  gi|14149669  
MITOGEN-ACTIVATED 
PROTEIN KINASE KINASE 
KINASE 7 INTERACTING 
PROTEIN 2 2 2 1 
RANBP10 57610 Q6VN20 gi|40538736  RAN BINDING PROTEIN 10 2 4 1 
RAVER1* 125950 Q8IY67  gi|123173757 RAVER1 2 4 1 
TUBA1A 203068 P07437  gi|340021 TUBULIN, ALPHA 2 2 3 
ZNF703 80139  gi|13376610 ZINC FINGER PROTEIN 703 2 3 1 
Table 1. Proteins captured with IIb in megakaryocytes and HEK293 cells. Results are 
separated according to the IIb subunit they were captured with. Column labels: Gene 
www.intechopen.com
 Mechanisms of IIb3 Biogenesis in the Megakaryocyte: A Proteomics Approach 
 
187 
Symbol, EntrezGene ID, Protein Accession Number and Description are from the NCBI 
database. SwissProt Accession Number is from the UniProt database. Number of Unique 
Peptides is cumulative from all experiments. Coverage percent is cumulative for all 
experiments. Tally is shown of the total number of experiments in which a protein was 
identified (No Expts), and whether captured by histidine tag/Ni affinity (Ni-His) or by 
crosslinking (X-link). Presence or absence in a recently published expression study 
(HaemAtlas) is indicated. * Proteins captured by both normal and mutant IIb subunits. 
3.2 Gene Ontology analysis 
Gene Ontology (GO) analysis using the DAVID Bioinformatics Resources(Dennis, Sherman 
et al. 2003; Huang, Sherman et al. 2008) revealed enrichment for protein functions related to 
processing and trafficking, and ER, Golgi or vesicle components (Figure 3). Comparison of 
the proteins isolated with the normal IIb subunits vs with the IIbR858G/R859G subunits 
showed similar distributions of their localization and molecular functions (Table 2). 
Notably, the IIbR858G/R859G subunits captured a greater percentage of these types of 
proteins, suggesting that a greater percentage of the IIbR858G/R859G subunits were 
associated with the ER, Golgi and vesicles. Comparison of our data set to a recently 
published analysis of gene expression in megakaryocytes(Watkins, Gusnanto et al. 2009) 
showed that approximately 70% of the proteins identified herein as potentially interacting 
with IIb were identified as expressed in the megakaryocyte transcriptome.  
 
GO function/location % of total proteins 
  IIb IIbR858G/R859G 
Protien transport 31 49 
Stress Caperone 21 34 
Vesicle part 6 14 
ER or Golgi part 19 21 
Organelle part 27 41 
Cytoskeleton 21 29 
ATP/GTP binding 31 45 
Table 2. Distribution of captured proteins into Gene Ontology categories. Some proteins 
appear in more than one category. 
Despite the similarity in distributions into GO categories pertaining to protein processing 
and localization, there were only 14 proteins in common between the normal IIb and 
IIbR858G/R859G captured proteins (Table 1). This may indicate a difference in the relative 
amount of time spent by the normal and mutant subunits in the protein processing 
environment. One protein, DNAJC10, was captured in all experiments by both IIb and 
IIbR858G/R859G. Like other DNAJ proteins, DNAJC10 contains a binding domain for the 
chaperone BiP, but is unique in that its second domain has four protein-disulfide-isomerase 
(PDI) consensus sequences. (Cunnea, Miranda-Vizuete et al. 2003; Dong, Bridges et al. 2008)  
Because disulfide bond rearrangement is important for both biogenesis and function of 
IIb3, we investigated the putative interaction between IIb and DNAJC10. To our 
knowledge, DNAJC10 has not previously been reported to interact with IIb or 3. 
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3.3 DNAJC10 interacts with IIb3 during biogenesis 
DNAJC10 coimmunoprecipitated with IIb and 3 from UCB derived megakaryocytes 
using anti-IIb mAbs 10E5, B1B5, M148 and CA3, and the anti 3 mAb 7H2. DNAJC10 
either interacted with IIb and 3 directly or was part of a complex with them (Figure 3). 
Because DNAJC10 was captured by the IIbR858G/R859G subunit, we explored the 
possibility that DNAJC10 interacted with IIb prior to IIb3 complex formation and IIb 
cleavage to its mature form. We have previously shown that pro-IIb is degraded by the 
proteasome and that proteasome inhibition leads to an increase of pro-IIb within the cells. 
(Mitchell, Li et al. 2006) The undegraded pro-IIb is trapped in a “pre-degradation” state in 
which normally transient protein interactions, which usually lead to degradation, may 
become more long-lived and may be captured by co-immunoprecipitation. Incubation of 
megakaryocytes with MG132 resulted in increased DNAJC10 co-immunoprecipitation with 
IIb by all mAbs, but particularly M148 and CA3. Thus, DNAJC10 may associate with IIb 
early in biogenesis, before excess pro-IIb is targeted to the proteasome.  
 
Fig. 3. Network derived from Table 1 data. Proteins are represented as nodes (circles) 
labeled with their gene symbol, and putative protein interactions with IIb are indicated by 
thin green connecting lines. Thick blue lines and blues circles represent interactions or 
proteins, respectively, retrieved from online databases (Intact and NCBI) using the 
Cytoscape software. Arrow indicates DNAJC10. Figure prepared using Cytoscape. 
To test this possibility we used a panel of conformation-specific mAbs that we have 
previously used to track the conformational changes of IIb as it proceeds through 
biogenesis (Figure 3).(Mitchell, Li et al. 2007) Specifically: mAb10E5 binds to the IIb head 
region and recognizes both the pro-IIb3 and mature IIb3 complex; mAb 7E3 binds to 
the 3 head region and also recognizes both the pro- and mature complex; mAb B1B5 binds 
to the IIb tail and preferentially recognizes pro-IIb and pro-IIb3 complex, and mAb 
M148 preferentially recognizes mature IIb3 but its epitope is not known.(Mitchell, Li et al. 
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2007) To determine whether DNAJC10 interacts with IIb during a specific stage of 
biogenesis, IIb was immunoprecipitated from megakaryocytes in the presence of MG132 
using this panel of conformation-specific mAbs. DNAJC10 was most strongly 
coimmunoprecipitated by mAb B1B5, suggesting that DNAJC10 preferentially interacts with 
pro-IIb or the pro-IIb3 complex. In contrast, DNAJC10 coimmunoprecipitated less well 
with mAb M148, suggesting less interaction with mature IIb. DNAJC10 also interacted 
with the precursor and/or mature IIb3 complex, since it coimmunoprecipitated with the 
complex-specific mAb10E5. Since the ratio of pro-IIb3 to mature IIb3 is small in 
megakaryocytes,(Mitchell, Li et al. 2007) this binding pattern is consistent with DNAJC10 
having bound preferentially to the small amount of pro-IIb3 present in the cells. Together 
these findings suggest that DNAJC10 preferentially interacted with pro-IIb and the pro-
IIb3 complex, rather than the mature complex.  
 
 
 
Fig. 4. Interaction of DNAJC10 with IIb3 during biogenesis. A) Schematic of changing 
conformations of IIb3 as it progresses through biogenesis. B) Changing specificity of 3 
mAbs against IIb as it progresses through distinct conformations during biogenesis. B1B5 
preferentially recognizes pro-IIb, while M148 shows preference for mature IIb, and 10E5 
recognizes the heterodimer complex.C) Immunoprecipitation and Western blot of proteins 
isolated from megakaryocytes, as described in text. DNAJC10 coimmunoprecipitated 
preferentially with IIb that was pulled down by 10E5 and B1B5, but not M148, suggesting 
that DNAJC10 preferentially interacts with pro-IIb and pro-IIb3. The last lane is an IgG 
control. D) siRNA mediated knockdown of DNAJC10 increased surface expression of IIb3 
as measured by flow cytometry using an Alexa647-labeled anti-IIb3 mAb (10E5). 
Expression was increased by 25 +\- 11% (p=0.02, n=4) in UCB-derived megakaryocytes 
(UCB) and by 35 +\- 12% (p=0.01, n=3) in HEK293 cells (HEK293) compared to control 
siRNA transfection (CTL).  
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3.4 DNAJC10 depletion increases surface expression of IIb3  
To determine whether the IIb-DNAJC10 interaction had physiological relevance, we 
assessed its impact on the surface expression of IIb3 in megakaryocytes. siRNA mediated 
knockdown of DNAJC10 was performed on both human megakaryocytes derived from 
UCB and on HEK293 cells expressing normal IIb and 3. At least an 80% decrease in RNA 
level was achieved (data not shown). Knockdown of DNAJC10 increased IIb3 surface 
expression on megakaryocytes by 25% +/- 11% (n = 4, p = 0.02), and on HEK293 cells 
expressing IIb3 by 35% +/- 12% (n=4, p = 0.01) (Figure 3D). 
3.5 Intracellular localization of DNAJC10 in megakaryocytes 
DNAJC10 was localized within megakaryocytes by immunofluorescence microscopy 
(Figure 5). The distribution of DNAJC10 was compared to that of IIb, 3, and the ER and 
Golgi compartments. Both IIb and 3 were distributed throughout the ER as well as on the 
cell surface. DNAJC10 had a diffuse punctate distribution in the periphery of the cell, away 
from the nucleus, and colocalized with only a portion of aIIb and 3, consistent with their 
presumably transient interaction. There was partial overlap between the ER marker calnexin 
and DNAJC10, suggesting that part of the DNAJC10 distribution is outside the ER or at least  
 
Fig. 4. Intracellular localization of DNAJC10. Cultured megakaryocytes were fixed and 
immunostained as described in the text. DNAJC10 (Blue) exhibited a punctate staining in 
the periphery of the cells, away from the nucleus. There was partial overlap of DNAJC10 
with calnexin (Red) staining. IIb (Green) was distributed throughout the ER and cell 
surface. While IIb partially colocalized with the cis- and trans-Golgi, DNAJC10 did not.  
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separate from the distribution of calnexin in the ER. This finding was surprising since 
DNAJC10 has the ER-retention signal KDEL. DNAJC10 did not localize with markers for the 
cis- or trans-Golgi compartments.  
4. Discussion 
We have used a proteomics approach to identify novel proteins interacting with IIb in 
megakaryocytes. Two different constructs of IIb, representing normal IIb and pro-IIb 
subunits, were used to capture proteins interacting with both nascent and mature subunits. 
Megakaryocytes were derived from human UCB and used on day 8, which in our system 
yields high expression IIb3 on the surface but no proplatelet formation.(Mitchell, Li et al. 
2006) In all, 163 proteins were identified as potentially interacting with IIb subunits; 98 
were captured with normal IIb and 79 with aIIbR858/G859G, with 14 overlapping (Table 
1). Day 8 megakaryocytes express very high amounts of IIb, most of which is mature 
IIb3, resulting in a relatively small proportion of nascent IIb. However, a large 
proportion of the mutant aIIbR858/G859G subunits are retained within the cell and 
degraded. Thus the difference between the two protein lists could partly be due to their 
differences in localization within the cell. This may be reflected in the larger proportion of 
ER and Golgi related proteins that were captured with the mutant subunit (Table 2). Only a 
few intracellular proteins have been reported to interact with IIb and IIb3, most notably 
talin, calnexin, and calreticulin (Intact and NCBI). Our two-step protein capture method was 
designed to isolate proteins with low affinity binding to IIb, such as calnexin, while 
screening out higher affinity binding proteins, such as talin and 3. In accord with this 
expectation, both talin and 3 were identified in both the control and experimental lanes, 
and so were excluded from the final interaction list, while calnexin and calreticulin were 
identified only in the experimental lanes. Surprisingly, while DNAJC10 readily 
coimmunoprecipitates with IIb3 from megakaryocytes, we have been unable to replicate 
this finding in HEK293 cells transfected with IIb and 3, despite an abundance of 
DNAJC10 in HEK293 cells (data not shown). While this is in no way conclusive, it is 
suggestive of cell-specific interaction of IIb3 and DNAJC10 in megakaryocytes. 
Comparison of our experimental results with previously reported platelet proteomic data 
and IIb3 interaction data showed good correlation. About 70% of the proteins identified 
in our screens were reported as “present” in platelets in the Haem Atlas, a proteomic 
analysis of platelet protein content(Watkins, Gusnanto et al. 2009).  
Two protein capturing strategies were used, each with strengths and weaknesses. The two-
cell pull-down assay using Ni beads to capture poly-histidine-tagged IIb, allowed the use 
of mutant cDNA constructs, such as IIbR858G/R859G, as bait. However, by introducing a 
protein synthesized in HEK293 cells as bait, there was the potential for false positive 
identification of proteins that associated with IIb in the HEK293 cells but not in 
megakaryocytes. Since the interactions of chaperone proteins are typically of low affinity, 
these proteins were most likely cleared by the washing steps and did not appear in the 
control lanes. Another source of false positives was non-specific binding to the Ni beads. 
Proteins with poly-His sequences (such as DEAH boxes) or naturally occurring Ni binding 
activity (such as keratin) could have bound to the beads, constituting false positives. 
However, virtually all of these potential false positives appeared in the control lanes as well 
and were excluded from analysis. The photoreactive crosslinking assay was intended to 
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capture proteins in situ with IIb in megakaryocytes. While crosslinking experiments 
typically produce high numbers of false positives, in our experiments we identified low 
numbers of proteins from both the experimental and control lanes. The low yield may be 
due in part to the short crosslinking time used. We found that more than 15 minutes of UV 
exposure caused excessive protein degradation, while shorter exposure resulted in low 
crosslinking activity.  
Of the proteins captured using both IIb and IIbR858G/R859G the Hsp40-type chaperone 
protein, DNAJC10 (ERdj5), was notable due to its disulfide isomerase activity, since both 
IIb and 3 require disulfide bond rearrangement for both biogenesis and function. (Shen, 
Meunier et al. 2002; Cunnea, Miranda-Vizuete et al. 2003; Dong, Bridges et al. 2008) Among 
its several functions, the ER chaperone protein BiP protects nearly-folded proteins against 
aggregation by binding to exposed hydrophobic patches.(Hendershot 2004) The Hsp40 
chaperones bind to BiP and increase its efficiency of ATP hydrolysis, which allows BiP to 
release its substrate. DNAJC10 has been shown to be induced during ER stress, and may 
assist in delivering misfolded ER proteins to the proteasome for degradation.(Shen, Meunier 
et al. 2002; Cunnea, Miranda-Vizuete et al. 2003; Dong, Bridges et al. 2008)  
DNAJC10 coimmunoprecipitated with both IIb and 3 subunits in megakaryocytes, 
suggesting that it may bind the IIb3 complex. The immunoprecipitation pattern obtained 
using a panel of conformation-specific mAbs(Mitchell, Li et al. 2007) indicated that 
DNAJC10 preferentially interacted with pro-IIb or pro-IIb3 rather than mature IIb3. 
Together these findings suggest that DNAJC10 interacted with pro-IIb up to the point of 
complex formation, but not after pro-IIb cleavage (Figure 2). Thus DNAJC10 appears to be 
present and interacting with IIb at a critical decision point during IIb3 biogenesis, i.e. 
when pro-IIb will either form the mature IIb3 complex or be targeted to degradation.  
Surprisingly, the distribution of DNAJC10, which has a KDEL ER-localization signal, was 
not confined to the ER, as judged by the distribution of calnexin. To determine if DNAJC10 
was cycling to the Golgi and back, as many ER packaging proteins do, we looked for 
colocalization of DNAJC10 with cis and trans Golgi markers, and found none. The identity 
of the organelle(s) where DNAJC10 resides remains to be determined. 
Depletion of DNAJC10 by siRNA resulted in an increase in surface expression of IIb3 on 
both human megakaryocytes and transfected HEK293 cells (Figure 2D) Since DNAJC10 
depletion led to an increase in IIb3 surface expression, it appears to be a negative 
regulator of IIb3 surface expression. These findings make DNAJC10 an interesting and 
potentially targetable protein for perturbing IIb3 biogenesis. 
5. Conclusion 
While the details of DNAJC10-IIb interaction remain to be investigated, the current 
findings provide proof of principle that manipulation of early events in IIb biogenesis can 
result in altered expression levels of the mature IIb3 receptor, thereby setting a precedent 
for a novel approach to integrin-related therapy. These studies also support the validity of 
the data set, although other putative interactions must be explored for greater validation. 
We hope that the data set created will be a useful tool for studying integrin and 
megakaryocyte biology.  
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By deciphering the IIb3 biogenesis pathway we hope to gain an inroad into controlling 
the level of IIb3 expression on platelets with the long-term goal of developing novel anti-
thrombotic therapies. These types of therapy would not just inactivate the circulating 
platelets, but would modulate the megakaryocytes to make less adhesive platelets. One can 
imagine a scenario where patients at high risk of heart attack or stroke could be maintained 
on a drug that decreases their platelet IIb3 expression. Below a certain level of expression, 
platelet activation and aggregation would be diminished but not completely eliminated, 
resulting in an overall decrease in platelet thrombus formation but not complete loss of 
platelet function. This type of therapy could potentially have a greater safety profile than 
current therapies that summarily inactivate circulating platelets. 
This study also assembles some of the wide range of research methods available to 
hematology research. No single technique could have discovered, validated and explored 
the function of DNAJC10 in megakaryocytes: rather, a broad range of methods was 
required. This wide variety is part of what makes research exciting and underscores the 
benefits of collaboration.  
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